Novel Cathepsin K Inhibitor Promising for OA

Patients treated with MIV-711 did have increases in parathyroid hormone levels and decreases in calcium levels, findings that were consistent with the expected mechanism of action of MIV-711.

The researchers concluded their paper by calling for future studies to determine if the structural benefits they observed will translate into more tangible benefits on OA symptoms.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Reference

Conaghan PG, Bowes MA, Kingsbury SR, et al. Disease-modifying effects of a novel cathepsin K inhibitor in osteoarthritis: A randomized controlled trial. Ann Intern Med. 2020 Jan 21;172(2):86–95.

For young patients especially, this can delay knee replacement and provide better outcomes.

CHICAGO—Are effective treatments for osteoarthritis (OA) on the horizon? In Emerging Treatments for Osteoarthritis at the 2018 ACR/ARHP Annual Meeting, experts discussed potential therapies to address OA structural progression, pain and inflammation. With an aging population and rising obesity rates, “we can expect the prevalence of osteoarthritis will only increase,” said Anne-Marie Malfait, MD, PhD,…

Overview of OA pathogenesis, recent discoveries suggest new treatment strategies are possible

CHICAGO—Joint trauma is one of many potential drivers of osteoarthritis disease activity and structural progression. In Post-Traumatic OA: Pathogenesis, Clinical Evolution and Management, a session at the 2018 ACR/ARHP Annual Meeting, experts discussed the effects of sports and other injuries on even young patients’ joints. Post-traumatic osteoarthritis (OA) may account for 12% of hip, knee…

Basics of Biologic Joint Reconstruction

Emerging Treatments for OA: New Therapies Target Joint Pain, Not Just Structural Damage

New Therapeutics for Osteoarthritis May Be in Sight

Post-Traumatic Osteoarthritis: Managing OA That Develops After Joint Injuries & Reconstructive Surgery

Related Articles